Ankur Bhadekar

First of all, congratulations for the good set of numbers. So, a couple of questions from my side. One was during the quarter, the onco API contribution has been low, around like 8% or so. So, I wanted to know the reason behind the same . And also, do we still hold a higher market share in the gemcitabine API?

Okay. And how do you look at the business going forward in terms of the Bio business? Like with Eight Roads coming in, what is your future growth strategy? And like how do you see the contribution from the Bio business going ahead?

First of all, congratulations for the good set of numbers. So, a couple of questions from my side. One was during the quarter, the onco API contribution has been low, around like 8% or so. So, I wanted to know the reason behind the same . And also, do we still hold a higher market share in the gemcitabine API?

Okay. And how do you look at the business going forward in terms of the Bio business? Like with Eight Roads coming in, what is your future growth strategy? And like how do you see the contribution from the Bio business going ahead?